Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 28:41:100418.
doi: 10.1016/j.jcte.2025.100418. eCollection 2025 Sep.

Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages

Hána Václav Jr  1 , Vaněčková Manuela  2 , Kršek Michal  1 , Krausová Adéla  1 , Ježková Jana  3 , Kosák Mikuláš  3 , Diblík Pavel  4 , Netuka David  5 , Masopust Václav  5 , Májovský Martin  5 , Liščák Roman  6 , Hána Václav  1
Affiliations

Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages

Hána Václav Jr et al. J Clin Transl Endocrinol. .

Abstract

Objectives: Dopamine agonists serve as first-line therapies for most giant prolactinomas. The objective of this study was to assess the differential impact of dopamine agonist dosing strategies on biochemical (prolactin normalisation) and radiological (tumour size reduction) responses in patients with giant prolactinomas.

Design: A single-centre retrospective real-life 23-year follow-up study.

Methods: Thirty-three patients with giant prolactinomas (≥ 4 cm) were treated with primary pharmacotherapy. We assessed pituitary function, the effect of therapy and different dosing regimens on prolactin normalisation and tumour size, the effect of surgery for complications and the effect of radiotherapy in resistant patients.

Results: Out of thirty-three consecutive patients (mean age 42 years), 27 were men, and 6 were women. The baseline mean prolactin concentration was 7506 µg/L. The treatment of choice was cabergoline in 30 patients, terguride in 2 patients, and bromocriptine in 1 patient. In patients receiving a high dose of cabergoline (3.5 mg weekly), we observed a faster normalisation of prolactin but not faster reduction in tumour size than in patients receiving a low dose (1-2.5 mg weekly). A total of 9/33 (27 %) patients underwent surgery for complications, 3 of whom were irradiated by Leksell gamma knife for partial resistance. In 4/33 patients we were able to stop pharmacotherapy after 10-20 years of treatment. The remaining 29/33 patients remained on pharmacological treatment.

Conclusions: Dopamine agonists are safe and only required treatment in 2/3 of patients treated with pharmacotherapy as a first-line treatment. Higher doses of cabergoline accelerate prolactin normalisation but do not confer additional benefit in early tumour shrinkage.

Keywords: Dopamine agonist; Giant prolactinoma; Hypogonadism; PitNET.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Therapy used in the treatment of giant prolactinomas.
Fig. 2
Fig. 2
Giant prolactinoma shrinkage after 3 months and 4 years of cabergoline therapy. An additional finding was a giant choroidal cyst.
See this image and copyright information in PMC

References

    1. Maiter D., Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170(6):R213–R227. doi: 10.1530/EJE-14-0013. - DOI - PubMed
    1. Shimon I., Benbassat C., Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. 2007;156(2):225–231. doi: 10.1530/EJE-06-0646. - DOI - PubMed
    1. Chanson P., Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2) doi: 10.1016/j.beem.2019.101290. - DOI - PubMed
    1. Paepegaey A.C., Salenave S., Kamenicky P., et al. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J Endocr Soc. 2017;1(3):221–230. doi: 10.1210/js.2017-00038. - DOI - PMC - PubMed
    1. Espinosa E., Sosa E., Mendoza V., Ramírez C., Melgar V., Mercado M. Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine. 2016;52(3):652–659. doi: 10.1007/S12020-015-0791-7/TABLES/4. - DOI - PubMed

LinkOut - more resources